In Brief: FDA Biological Response Modifiers Committee
This article was originally published in The Gray Sheet
FDA Biological Response Modifiers Committee: Slated to meet Feb. 28 and 29 at the Holiday Inn in Bethesda, Maryland. On Feb. 28 the committee will discuss a premarket approval application for CellPro's Ceprate SC device for selection of CD34+ progenitor/stem cells and receive an update on "stem cell policy," according to a Jan. 31 notice in the Federal Register. On Feb. 29 the committee will discuss issues in early clinical trial development for in utero stem cell transplantation and the draft addendum to the 1991 points-to-consider on human somatic cell and gene therapy. Contact FDA's William Freas or Pearline Muckelvgene, 301/827-0314...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.